14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
08:00 , Dec 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Annexin A1 (ANXA1)

Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Patient sample, cell culture and mouse studies suggest neutrophil-derived ANXA1-positive microvesicles could help treat RA. In patients, numbers of neutrophil-derived ANXA1-positive microvesicles were higher in synovial tissues than in...
08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Annexin A1 (ANXA1)

Cardiovascular disease INDICATION: Atherosclerosis Mouse studies suggest plaque-targeting nanoparticles loaded with an ANXA1 peptide could help prevent cardiac events in atherosclerosis patients. Nanoparticles targeting the collagen type IV component of atherosclerotic plaques were loaded with...
07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Annexin A1 (ANXA1)-mediated drug transport into tumors In vitro and mouse studies suggest targeting cancer therapeutics to ANXA1 could enable their active transport into tumors....
07:00 , Aug 21, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Dermatology Annexin A1 (ANXA1); formyl peptide receptor 1 (FPR1) Cell culture studies suggest inhibiting ANXA1 or its receptor FPR1 could help treat drug-induced adverse cutaneous...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Health Diagnostic Laboratory, Oncimmune deal

Health Diagnostic acquired "substantially all" of the assets of Oncimmune's Oncimmune USA LLC subsidiary. As part of the deal, all 25 employees of the subsidiary will join Health Diagnostic. Oncimmune also granted Health Diagnostic exclusive,...
08:00 , Jan 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Multiple sclerosis (MS) Annexin A1 (ANXA1) Patient sample and mouse studies suggest ANXA1 could help restore blood brain barrier (BBB) integrity...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Clinical News

EarlyCDT-Lung update

By year end, Oncimmune will begin a prospective screening trial to evaluate the cost-effectiveness of EarlyCDT-Lung test in detecting early lung cancer in about 10,000 high-risk smokers (defined as having smoked the equivalent of 20...
08:00 , Dec 8, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Annexin A1 (ANXA1) Studies in mice identified an ANXA1-targeted peptide that could help treat cancer. In mice with tumors, injection of a phage library...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

EarlyCDT-Lung diagnostic data

An international validation study in 3 cohorts of patients in the U.S. and Russia; Germany; and the U.S., U.K. and Ukraine, respectively, with newly diagnosed lung cancer (n=145, 241 and 269) showed that Oncimmune's EarlyCDT-Lung...